印度重型肠道热的疾病经济负担
本研究在印度14家医院(3级城市转诊医院与2级城市贫民区、偏远农村及部落地区医院)识别血培养确诊的肠道热住院患者及非创伤性回肠穿孔患者,收集发病至出院后28天的疾病成本与生产力损失数据。结果显示,2级机构重型肠道热平均直接成本为119.1美元(95%CI 85.8-152.4),3级机构为405.7美元(95%CI 366.9-444.4),3级机构中16.9%的患者发生灾难性支出。作者认为肠道热治疗成本可观,并可能随抗菌药物耐药性出现而增加,亟需公平的预防策略。
要点
- 2级机构重型肠道热平均直接成本为119.1美元(95%CI 85.8-152.4)。
- 3级机构重型肠道热平均直接成本为405.7美元(95%CI 366.9-444.4),16.9%患者发生灾难性支出。
- 作者认为肠道热治疗成本可观且可能随抗菌药物耐药性增加,亟需公平预防策略。
核心结论
- 作者认为肠道热治疗成本可观,并可能随抗菌药物耐药性出现而增加,亟需公平的预防策略。
研究设计与样本
- 在印度14家医院(3级城市转诊医院与2级城市贫民区、偏远农村及部落地区医院)识别血培养确诊的肠道热住院患者及非创伤性回肠穿孔患者。
- 使用结构化问卷收集发病至出院后28天的疾病成本与生产力损失数据,按机构类型分析一次发作的直接与间接成本。
主要发现
- 2级监测共274例患者、3级监测共891例患者及110例回肠穿孔患者提供了疾病成本数据。
- 重型肠道热平均直接成本在2级机构为119.1美元(95%CI 85.8-152.4),在3级机构为405.7美元(95%CI 366.9-444.4)。
- 3级机构中16.9%的患者发生灾难性支出。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Lack of robust data on economic burden due to enteric fever in India has made decision making on typhoid vaccination a challenge. Surveillance for Enteric Fever network was established to address gaps in typhoid disease and economic burden. METHODS: Patients hospitalized with blood culture-confirmed enteric fever and nontraumatic ileal perforation were identified at 14 hospitals. These sites represent urban referral hospitals (tier 3) and smaller hospitals in urban slums, remote rural, and tribal settings (tier 2). Cost of illness and productivity loss data from onset to 28 days after discharge from hospital were collected using a structured questionnaire. The direct and indirect costs of an illness episode were analyzed by type of setting. RESULTS: In total, 274 patients from tier 2 surveillance, 891 patients from tier 3 surveillance, and 110 ileal perforation patients provided the cost of illness data. The mean direct cost of severe enteric fever was US$119.1 (95% confidence interval [CI], US$85.8-152.4) in tier 2 and US$405.7 (95% CI, 366.9-444.4) in tier 3; 16.9% of patients in tier 3 experienced catastrophic expenditure. CONCLUSIONS: The cost of treating enteric fever is considerable and likely to increase with emerging antimicrobial resistance. Equitable preventive strategies are urgently needed.
引用
- Kumar D, Sharma A, Rana SK, et al. Cost of Illness Due to Severe Enteric Fever in India. J Infect Dis. 2021. PMID: 35238366. doi:10.1093/infdis/jiab282
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。